These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31617224)

  • 1. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
    Boursier J; Vergniol J; Guillet A; Hiriart JB; Lannes A; Le Bail B; Michalak S; Chermak F; Bertrais S; Foucher J; Oberti F; Charbonnier M; Fouchard-Hubert I; Rousselet MC; Calès P; de Lédinghen V
    J Hepatol; 2016 Sep; 65(3):570-8. PubMed ID: 27151181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis.
    Calès P; Boursier J; Oberti F; Moal V; Fouchard Hubert I; Bertrais S; Hunault G; Rousselet MC;
    Hepatol Commun; 2018 Apr; 2(4):455-466. PubMed ID: 29619423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
    Broussier T; Lannes A; Zuberbuhler F; Oberti F; Fouchard I; Hunault G; Cales P; Boursier J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):349-355. PubMed ID: 31422033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
    Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
    Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
    Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of blood tests for liver fibrosis specific or not to NAFLD.
    Calès P; Lainé F; Boursier J; Deugnier Y; Moal V; Oberti F; Hunault G; Rousselet MC; Hubert I; Laafi J; Ducluzeaux PH; Lunel F
    J Hepatol; 2009 Jan; 50(1):165-73. PubMed ID: 18977552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Dincses E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
    Boursier J; Canivet CM; Costentin C; Lannes A; Delamarre A; Sturm N; Le Bail B; Michalak S; Oberti F; Hilleret MN; Irles-Depé M; Fouchard I; Hermabessiere P; Barthelon J; Calès P; Cariou B; de Ledinghen V; Roux M
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1243-1251.e12. PubMed ID: 35288342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.